Dowlais Group Valuation
Is 6O7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6O7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6O7 (€0.63) is trading below our estimate of fair value (€2.74)
Significantly Below Fair Value: 6O7 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6O7?
Other financial metrics that can be useful for relative valuation.
| What is 6O7's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | n/a |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 5.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 6O7's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.3x | ||
SFQ SAF-Holland | 0.3x | 3.2% | €633.7m |
NVM Novem Group | 0.5x | 1.4% | €275.4m |
ZIL2 ElringKlinger | 0.1x | 2.2% | €255.7m |
ED4 EDAG Engineering Group | 0.2x | 4.7% | €200.0m |
6O7 Dowlais Group | 0.1x | -0.4% | €648.7m |
Price-To-Sales vs Peers: 6O7 is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.3x).
Price to Earnings Ratio vs Industry
How does 6O7's PE Ratio compare vs other companies in the European Auto Components Industry?
Price-To-Sales vs Industry: 6O7 is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Auto Components industry average (0.3x).
Price to Sales Ratio vs Fair Ratio
What is 6O7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.1x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 6O7's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €0.63 | €1.00 +58.8% | 17.8% | €1.19 | €0.69 | n/a | 10 |
| Oct ’25 | n/a | €1.12 0% | 19.8% | €1.50 | €0.74 | n/a | 10 |
| Sep ’25 | n/a | €1.10 0% | 20.3% | €1.47 | €0.73 | n/a | 10 |
| Aug ’25 | n/a | €1.34 0% | 23.2% | €1.96 | €0.93 | n/a | 10 |
| Jul ’25 | n/a | €1.36 0% | 23.4% | €1.94 | €0.92 | n/a | 10 |
| Jun ’25 | n/a | €1.37 0% | 22.0% | €1.94 | €0.93 | n/a | 10 |
| May ’25 | n/a | €1.46 0% | 23.8% | €2.04 | €0.92 | n/a | 10 |
| Apr ’25 | n/a | €1.46 0% | 23.6% | €2.05 | €0.92 | n/a | 10 |
| Mar ’25 | n/a | €1.61 0% | 27.0% | €2.34 | €0.97 | n/a | 10 |
| Feb ’25 | n/a | €1.67 0% | 26.6% | €2.34 | €0.97 | n/a | 9 |
| Jan ’25 | n/a | €1.68 0% | 25.9% | €2.32 | €1.04 | n/a | 9 |
| Dec ’24 | n/a | €1.69 0% | 23.0% | €2.28 | €1.11 | n/a | 9 |
| Nov ’24 | n/a | €1.73 0% | 23.2% | €2.29 | €1.11 | €0.63 | 9 |
| Oct ’24 | n/a | €1.87 0% | 22.6% | €2.54 | €1.12 | n/a | 9 |
| Sep ’24 | n/a | €1.92 0% | 23.5% | €2.56 | €1.13 | n/a | 8 |
| Aug ’24 | n/a | €1.92 0% | 23.3% | €2.56 | €1.13 | n/a | 8 |
| Jul ’24 | n/a | €1.98 0% | 18.1% | €2.58 | €1.35 | n/a | 8 |
| Jun ’24 | n/a | €1.99 0% | 18.8% | €2.56 | €1.34 | n/a | 7 |
| May ’24 | n/a | €1.93 0% | 12.3% | €2.26 | €1.63 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.